This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
HLN vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
HLN vs. SYK: Which Stock Is the Better Value Option?
Down 7.4% in 4 Weeks, Here's Why Haleon PLC Sponsored ADR (HLN) Looks Ripe for a Turnaround
by Zacks Equity Research
Haleon PLC Sponsored ADR (HLN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B
by Zacks Equity Research
Pfizer divests its 7.3% remaining stake in Haleon to institutional investors and Haleon itself.
AHCO vs. HLN: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. HLN: Which Stock Is the Better Value Option?
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
by Kinjel Shah
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.
HLN or PODD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HLN vs. PODD: Which Stock Is the Better Value Option?
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
by Zacks Equity Research
Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.